StockData
Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc. (DRMA) stock

DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.57−0.03 (-4.75%)

Close on Nov 17, 2026Market cap $2.29MP/E –Yield –

Dermata Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Dermata Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$8.60M. For fiscal 2025 it was -$7.77M. The highest annual figure on record is -$3.17M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.77M–
FY2024Dec 31, 2024-$12.51M–
FY2023Dec 31, 2023-$8.04M–
FY2022Dec 31, 2022-$9.67M–
FY2021Dec 31, 2021-$7.86M–
FY2020Dec 31, 2020-$3.17M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.01M–
Q1 FY2026Mar 31, 2026-$1.93M–
Q4 FY2025Dec 31, 2025-$1.90M–
Q3 FY2025Sep 30, 2025-$1.76M–
Q2 FY2025Jun 30, 2025-$1.77M–
Q1 FY2025Mar 31, 2025-$2.34M–
Q4 FY2024Dec 31, 2024-$3.20M–
Q3 FY2024Sep 30, 2024-$3.23M–
Q2 FY2024Jun 30, 2024-$2.88M–
Q1 FY2024Mar 31, 2024-$3.20M–
Q4 FY2023Dec 31, 2023-$2.22M–
Q3 FY2023Sep 30, 2023-$1.81M–
Q2 FY2023Jun 30, 2023-$1.73M–
Q1 FY2023Mar 31, 2023-$2.28M–
Q4 FY2022Dec 31, 2022-$1.71M–
Q3 FY2022Sep 30, 2022-$2.45M–
Q2 FY2022Jun 30, 2022-$2.73M–
Q1 FY2022Mar 31, 2022-$2.79M–
Q4 FY2021Dec 31, 2021-$2.55M–
Q3 FY2021Sep 30, 2021-$1.71M–
Q2 FY2021Jun 30, 2021-$1.33M–
Q1 FY2021Mar 31, 2021-$2.26M–
Q4 FY2020Dec 31, 2020-$491.43K–
Q3 FY2020Sep 30, 2020-$540.06K–
Q2 FY2020Jun 30, 2020-$792.79K–

More Dermata Therapeutics figures

See a number that looks wrong?